Contact
Please use this form to send email to PR contact of this press release:
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
TO:
Please use this form to send email to PR contact of this press release:
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
TO: